217 related articles for article (PubMed ID: 34016731)
1.
Zaragori T; Oster J; Roch V; Hossu G; Chawki MB; Grignon R; Pouget C; Gauchotte G; Rech F; Blonski M; Taillandier L; Imbert L; Verger A
J Nucl Med; 2022 Jan; 63(1):147-157. PubMed ID: 34016731
[TBL] [Abstract][Full Text] [Related]
2. Implementing the Point Spread Function Deconvolution for Better Molecular Characterization of Newly Diagnosed Gliomas: A Dynamic
Ahrari S; Zaragori T; Bros M; Oster J; Imbert L; Verger A
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497245
[TBL] [Abstract][Full Text] [Related]
3. Integration of dynamic parameters in the analysis of
Ginet M; Zaragori T; Marie PY; Roch V; Gauchotte G; Rech F; Blonski M; Lamiral Z; Taillandier L; Imbert L; Verger A
Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1381-1390. PubMed ID: 31529264
[TBL] [Abstract][Full Text] [Related]
4. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
Chen SC; Lo CM; Wang SH; Su EC
BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
[TBL] [Abstract][Full Text] [Related]
5. Static
Song S; Wang L; Yang H; Shan Y; Cheng Y; Xu L; Dong C; Zhao G; Lu J
Eur Radiol; 2021 Jun; 31(6):4087-4096. PubMed ID: 33211141
[TBL] [Abstract][Full Text] [Related]
6. Radiomics-Based Method for Predicting the Glioma Subtype as Defined by Tumor Grade, IDH Mutation, and 1p/19q Codeletion.
Li Y; Ammari S; Lawrance L; Quillent A; Assi T; Lassau N; Chouzenoux E
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406550
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia and glucose metabolism assessed by FMISO and FDG PET for predicting IDH1 mutation and 1p/19q codeletion status in newly diagnosed malignant gliomas.
Suzuki K; Kawai N; Ogawa T; Miyake K; Shinomiya A; Yamamoto Y; Nishiyama Y; Tamiya T
EJNMMI Res; 2021 Jul; 11(1):67. PubMed ID: 34291337
[TBL] [Abstract][Full Text] [Related]
8. The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas.
Zhao K; Sun G; Wang Q; Xue Z; Liu G; Xia Y; Yao A; Zhao Y; You N; Yang C; Xu B
Acad Radiol; 2021 Jul; 28(7):e189-e198. PubMed ID: 32359929
[TBL] [Abstract][Full Text] [Related]
9. Multi-parametric Z-spectral MRI may have a good performance for glioma stratification in clinical patients.
Su C; Xu S; Lin D; He H; Chen Z; Damen FC; Ke C; Lv X; Cai K
Eur Radiol; 2022 Jan; 32(1):101-111. PubMed ID: 34272981
[TBL] [Abstract][Full Text] [Related]
10. Preoperative Radiomics Analysis of 1p/19q Status in WHO Grade II Gliomas.
Fan Z; Sun Z; Fang S; Li Y; Liu X; Liang Y; Liu Y; Zhou C; Zhu Q; Zhang H; Li T; Li S; Jiang T; Wang Y; Wang L
Front Oncol; 2021; 11():616740. PubMed ID: 34295805
[TBL] [Abstract][Full Text] [Related]
11. Static and dynamic
Verger A; Stoffels G; Bauer EK; Lohmann P; Blau T; Fink GR; Neumaier B; Shah NJ; Langen KJ; Galldiks N
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):443-451. PubMed ID: 29043400
[TBL] [Abstract][Full Text] [Related]
12. [Prediction of 1p/19q codeletion status in diffuse lower-grade glioma using multimodal MRI radiomics].
Lu M; Qu Y; Ma A; Zhu J; Zou X; Lin G; Li Y; Liu X; Wen Z
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Jun; 43(6):1023-1028. PubMed ID: 37439176
[TBL] [Abstract][Full Text] [Related]
13. Impact of signal intensity normalization of MRI on the generalizability of radiomic-based prediction of molecular glioma subtypes.
Foltyn-Dumitru M; Schell M; Rastogi A; Sahm F; Kessler T; Wick W; Bendszus M; Brugnara G; Vollmuth P
Eur Radiol; 2024 Apr; 34(4):2782-2790. PubMed ID: 37672053
[TBL] [Abstract][Full Text] [Related]
14. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
[TBL] [Abstract][Full Text] [Related]
15. MRI radiomics analysis of molecular alterations in low-grade gliomas.
Shofty B; Artzi M; Ben Bashat D; Liberman G; Haim O; Kashanian A; Bokstein F; Blumenthal DT; Ram Z; Shahar T
Int J Comput Assist Radiol Surg; 2018 Apr; 13(4):563-571. PubMed ID: 29270916
[TBL] [Abstract][Full Text] [Related]
16. Dynamic
Zaragori T; Doyen M; Rech F; Blonski M; Taillandier L; Imbert L; Verger A
Front Oncol; 2021; 11():735257. PubMed ID: 34676168
[TBL] [Abstract][Full Text] [Related]
17.
Zhao K; Yu P; Xue Z; Liu J; Yao A; Zhao Y; Yang F; Tian J; Xu B
Acad Radiol; 2020 Jul; 27(7):e159-e167. PubMed ID: 31607471
[TBL] [Abstract][Full Text] [Related]
18. Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas.
Yang X; Lin Y; Xing Z; She D; Su Y; Cao D
Acta Radiol; 2021 Dec; 62(12):1657-1665. PubMed ID: 33222488
[TBL] [Abstract][Full Text] [Related]
19. Integrated CT Radiomics Features Could Enhance the Efficacy of
Zhou W; Huang Q; Wen J; Li M; Zhu Y; Liu Y; Dai Y; Guan Y; Zhou Z; Hua T
Front Oncol; 2021; 11():772703. PubMed ID: 34869011
[TBL] [Abstract][Full Text] [Related]
20. Differentiating high-grade glioma progression from treatment-related changes with dynamic [
Rozenblum L; Zaragori T; Tran S; Morales-Martinez A; Taillandier L; Blonski M; Rech F; Galanaud D; Kas A; Verger A
Eur Radiol; 2023 Apr; 33(4):2548-2560. PubMed ID: 36367578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
